Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Autor:
Roi Dagan, Rebecca L. Green, S. Patel, Samip Patel, Emily C. Goldman, Jared Weiss, Nathan C. Sheets, Jeff Blumberg, Adam M. Zanation, Mark C. Weissler, Trevor Hackman, Gaorav P. Gupta, Sunil Kumar, William M. Mendenhall, Brian D. Thorp, Bhishamjit S. Chera, Colette J. Shen, Juneko E. Grilley-Olson, Xianming M. Tan, Wendell G. Yarbrough, Robert J. Amdur
Publikováno v:
Journal of Clinical Oncology
J Clin Oncol
J Clin Oncol
PURPOSE Plasma circulating tumor human papillomavirus DNA (ctHPVDNA) is a sensitive and specific biomarker of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). We investigated whether longitudinal monitoring of ctHP
Autor:
Irena Lanc, Ken A. Olaussen, Anne McLeer-Florin, Gwénaël Le Teuff, Federico Rotolo, Ming-Sound Tsao, Lesley Seymour, Keyue Ding, Robert A. Kratzke, Stephen L. Graziano, Siddhartha Devarakonda, Stefan Michiels, Frances A. Shepherd, Robert S. Fulton, Shingo Sakashita, Jean Pierre Pignon, Elisabeth Brambilla, Jean-Charles Soria, Ramaswamy Govindan, Ashiq Masood
Purpose The survival benefit with adjuvant chemotherapy for patients with resected stage II-III non–small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive biomarkers in these patients have not yielded clinically usefu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94c1309cdf0e5b911e816eb3b814842
https://europepmc.org/articles/PMC6804865/
https://europepmc.org/articles/PMC6804865/
Autor:
Wei Zhou, Conor N. Gruber, Che-Kai Tsao, Timothy B. Lannin, Brian Kirby, Atef Zaher, Karla V. Ballman, Scott T. Tagawa, Giuseppe Galletti, Costantine Albany, Yang Bai, Ada Gjyrezi, Guru Sonpavde, Shalu Suri, Mario A. Eisenberger, David M. Nanus, Daniel Worroll, Marie Vanhuyse, Paraskevi Giannakakou, Shinsuke Tasaki, Luigi Portella, Erica D. Pratt, Scott North, Ted H. Szatrowski, John Stewart, Fred Saad, Emmanuel S. Antonarakis
Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance to taxanes in men with ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c546985a80df4dfdae8e28d9af6ad0b
https://europepmc.org/articles/PMC5791829/
https://europepmc.org/articles/PMC5791829/